Home / Guidelines / FDA issues guidance on quality considerations for inhaled drugs
FDA issues guidance on quality considerations for inhaled drugs Posted 15/06/2018

The US Food and Drug Administration (FDA) has issued draft guidance on quality considerations for inhaled drugs.
The aim of the guidance is to provide recommendations to industry on the development and manufacture of both brand-name and generic inhalation aerosols [also known as metered dose inhalers (or MDIs) and inhalation powders (also known as dry powder inhalers (or DPIs)]. The agency also points out that the recommendations in the guidance can apply to MDI and DPI products intended for local or systemic effect. It does not, however, discuss aqueous-based nasal spray drug products and inhalation solution, suspension and spray drug products or the manufacture of drug substances.
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products – Quality Considerations Rev 1 The guidance stipulates that sponsors should create a desired quality target product profile (QTPP) before development begins. This, the agency says, should include elements such as strength, purity and stability, aerodynamic performance and the proposed dosage form and delivery system. Early in the development process, applicants should also develop a list of potential critical quality attributes (CQAs) within appropriate limits. Each CQA should relate to one or more elements of the product QTPP. For example: Knowledge of the QTPP for the product, in combination with information from prior knowledge, risk assessments and/or experimentation, can be used to develop the list of product CQAs. The list of product CQAs can be modified as product development progresses and new knowledge is gained.
Related articles FDA calls for comment on generics user fees guidelines Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.
Date: April 2018
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070573.pdf
FDA issues guidance on good manufacturing practice for APIs
Source: US FDA
Comments (0)
Generics News Research General
- The impact of generics regulation in BrazilGenerics/Research | Posted 13/12/2019
- Ontario proposes regulatory changes to simplify...Generics/General | Posted 13/12/2019
- EMA recommends approval for two new genericsGenerics/News | Posted 06/12/2019
- FDA generics approvals increasing but not for a...Generics/Research | Posted 29/11/2019
Biosimilars News Research General
- FDA approval for Amgen’s infliximab biosimilar...Biosimilars/News | Posted 13/12/2019
- Canadian gastroenterologists issue biosimilar p...Biosimilars/General | Posted 13/12/2019
- Bio-Thera gains Chinese approval for adalimumab...Biosimilars/News | Posted 13/12/2019
- Pharmacists must be ready to take the lead on b...Biosimilars/Research | Posted 13/12/2019